Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 September 2025
Human medicines European public assessment report (EPAR): Acvybra, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Degevma, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Denosumab Intas, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Gobivaz, golimumab, Status: Opinion
Human medicines European public assessment report (EPAR): Kefdensis, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Kyinsu, insulin icodec,semaglutide, Status: Opinion
Human medicines European public assessment report (EPAR): Lynkuet, elinzanetant, Status: Opinion
Human medicines European public assessment report (EPAR): Ponlimsi, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Rivaroxaban Koanaa, rivaroxaban, Status: Opinion